Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer

Autor: Diederich, Christian, Hsu, I-Chow, Zagar, TM, Vujaskovic, Z, Formenti, S, Rugo, H, Muggia, F, O'Connor, B, Myerson, R, Stauffer, P

Publikováno v: Diederich, Christian; Hsu, I-Chow; Zagar, TM; Vujaskovic, Z; Formenti, S; Rugo, H; et al.(2014). Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/7k29m0td

Unresectable chest wall recurrences of breast cancer (CWR) in heavily pretreated patients are especially difficult to treat. We hypothesised that thermally enhanced drug delivery using low temperature liposomal doxorubicin (LTLD), given with mild loc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::3b6e1a53f9aa84fc33416f207bc29828
http://www.escholarship.org/uc/item/7k29m0td

Breast cancer radiotherapy and coronary artery stenosis: location, location, location.

Autor: Zagar TM, Marks LB

Publikováno v: Journal of Clinical Oncology; 2/1/2012, Vol. 30 Issue 4, p350-352, 3p

Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007.

Autor: Dinan MA (AUTHOR), Robinson TJ (AUTHOR), Zagar TM (AUTHOR), Scales CD Jr (AUTHOR), Curtis LH (AUTHOR), Reed SD (AUTHOR), Lee WR (AUTHOR), Schulman KA (AUTHOR), Dinan, Michaela A¹ (AUTHOR), Robinson, Timothy J (AUTHOR), Zagar, Timothy M (AUTHOR), Scales, Charles D Jr (AUTHOR), Curtis, Lesley H (AUTHOR), Reed, Shelby D (AUTHOR), Lee, W Robert (AUTHOR), Schulman, Kevin A (AUTHOR)

Publikováno v: International Journal of Radiation Oncology, Biology, Physics. Apr2012, Vol. 82 Issue 5, pe781-6. 1p.

Prospective Assessment of Patient-Reported Dry Eye Syndrome After Whole Brain Radiation.

Autor: Wang K; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina. Electronic address: kwang545@gmail.com., Tobillo R; Florida Atlantic University College of Medicine, Boca Raton, Florida., Mavroidis P; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Pappafotis R; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Pearlstein KA; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Moon DH; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Mahbooba ZM; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Deal AM; Lineberger Comprehensive Cancer Center Biostatistics Core, University of North Carolina Hospitals, Chapel Hill, North Carolina., Holmes JA; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Sheets NC; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Kasibhatla MS; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Pacholke HD; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Royce TJ; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Weiner AA; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Shen CJ; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Zagar TM; Northeastern Radiation Oncology, Glens Falls, New York., Marks LB; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina., Chera BS; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, North Carolina.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2019 Nov 15; Vol. 105 (4), pp. 765-772. Date of Electronic Publication: 2019 Jul 24.

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.

Autor: Van Swearingen AED; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Siegel MB; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Deal AM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Sambade MJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Hoyle A; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Hayes DN; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA.; West Cancer Center, University of Tennessee, Knoxville, USA., Jo H; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Little P; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Dees EC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Muss H; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Jolly T; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Zagar TM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Patel N; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Miller CR; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Parker JS; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Smith JK; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Fisher J; Carolinas Medical Center, Charlotte, NC, USA., Shah N; MD Anderson Orlando, Orlando, FL, USA., Nabell L; University of Alabama, Birmingham, AL, USA., Nanda R; University of Chicago, Chicago, IL, USA., Dillon P; University of Virginia, Charlottesville, VA, USA., Abramson V; Vanderbilt University, Nashville, TN, USA., Carey LA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA., Anders CK; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599-7305, USA. carey_anders@med.unc.edu.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2018 Oct; Vol. 171 (3), pp. 637-648. Date of Electronic Publication: 2018 Jun 25.